Orphanet: Einfache Suche

Suche klinische Studie

Weitere Suchoptionen

176 Ergebnis(se)

Nationale klinische Studie(n)

EXIST-LT: Long-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301- BE Universitair Ziekenhuis Brussel Pediatric neurology / Neurologie Kinderen

NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - BE UZ Leuven - Campus Gasthuisberg Department of Human Genetics

EASE study: Double Blind, Randomised, Vehicle Controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa - BE UZ Leuven - Campus Gasthuisberg Reference centre for inherited Epidermolysis Bullosa

Effectiveness and safety of mTOR-inhibitor in patients with tuberous sclerosis complex-KD Universitätsklinikum Heidelberg

PazoQol: Lebensqualität bei Patienten mit nicht-adipozytärem Weichgewebssarkom unter palliativer Chemotherapie oder Pazopanib -eine randomisierte, kontrollierte Studie Helios Klinikum Emil von Behring Klinik für Onkologie

OlaReDo: Wirksamkeit von Olaratumab und Wiederauftreten mit Doxorubicin bei Anthrazyklin vorbehandelten, fortgeschrittenen Weichteilsarkompatienten. Eine explorative Phase-II-Studie Krankenhaus Nordwest GmbH Institut für Klinisch-Onkologische Forschung

EXIST-2: A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) - ES (Phase III) Institution: Information not provided - FR

Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 - FR CHU de Nantes CHU Nantes

EASE study: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel S10 in Patients with Inherited Epidermolysis Bullosa - IE Children's Health Ireland @ Crumlin Dermatology Department

European Paediatric Soft Tissue Sarcoma Study Group protocol for Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas 2005 (phase III) - IE Children's Health Ireland @ Crumlin National Oncology/ Bone Marrow Transplant Centre and Haematology Department

EASE study: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel S10 in Patients with Inherited Epidermolysis Bullosa - IE St James's Hospital Dermatology Department

A Phase 1/2 Study of ARQ 092 in Patients with Overgrowth Diseases and/or Vascular Anomalies with Genetic Alterations of the PI3K/AKT Pathway IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO Ambulatorio Polispecialistico per le Malattie Rare

High dose intravenous N-Acetylcysteine vs Iloprost for Early, rapidly progressive diffuse systemic Sclerosis Università Politecnica delle Marche - Polo Didattico Istituto di Clinica Medica

Low-dose oral Imatinib in the treatment of Scleroderma pulmonary involvement: a phase II pilot sutdy Università Politecnica delle Marche - Polo Didattico Istituto di Clinica Medica

RATE trial: Randomised open label cross-over study into the efficacy of rapamycin in children with Tuberous Sclerosis Complex with intractable epilepsy (phase II/III trial) Erasmus MC - Erasmus Medisch Centrum Afdeling Kinderneurologie

RAPIT trial: Efficacy of RAD001/everolimus in Autism and NeuroPsychological deficits in children with TSC (phase II/III trial) Erasmus MC - Erasmus Medisch Centrum Afdeling Kinderneurologie

NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL Erasmus MC - Erasmus Medisch Centrum Afdeling Kinderneurologie

NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL Erasmus MC - Erasmus Medisch Centrum Afdeling Neurowetenschappen

NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - BE Erasmus MC - Erasmus Medisch Centrum

EASE: Double Blind, Randomised, Vehicle Controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa - AT Universitätsklinikum der Paracelsus Medizinischen Privatuniversität EB-Haus Austria

REGO-SARC: Activity and Safety of Regorafenib in Patients With Metastatic Soft Tissue Sarcoma Previously Treated With Anthracycline-based Chemotherapy: a Multinational, Randomized, Phase II, Placebo-controlled Trial - AT Allgemeines Krankenhaus der Stadt Wien Klinische Abteilung für Onkologie

EASE study: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel S10 in Patients with Inherited Epidermolysis Bullosa - CH University Hospital Inselspital Poliklinik für Dermatologie

ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized,Double-Blinded) Study Evaluating Gemcitabine andDocetaxel With or Without Olaratumab in the Treatment ofAdvanced Soft Tissue Sarcoma -GB Institution: Information not provided - CH

PazoQol: Quality of life in patients with non-adipocyte soft tissue sarcoma underpalliative chemotherapy or pazopanib - a randomized, controlled trial - CH Institution: Information not provided - CH

GEIS-51: Phase II multicenter trial of palbociclib in second line of advanced sarcomas with CDK4 overexpression - ES Hospital Universitario Virgen del Rocío MUsculoSkeletal Tumor Board of Excellence Sevilla (MUSTBE SEVILLA)

EASE study: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel-S10 in Patients with Inherited Epidermolysis Bullosa - ES Hospital Viamed Santa Ángela de la Cruz Servicio de Dermatología

GEIS-51: Phase II multicenter trial of palbociclib in second line of advanced sarcomas with CDK4 overexpression - ES ICO Badalona - Hospital Germans Trias i Pujol Servicio de Oncología Médica

EASE study: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel-S10 in Patients with Inherited Epidermolysis Bullosa - ES Hospital Universitari Vall d'Hebron Servicio de Cirugía Plástica y Quemados

ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma - ES Hospital Universitari Vall d'Hebron Servicio de Oncología Médica

EASE study: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel-S10 in Patients with Inherited Epidermolysis Bullosa - ES Hospital Sant Joan de Déu Barcelona Servicio de Dermatología

A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects with Gorlin Syndrome (Basal Cell Nevus Syndrome) - ES Institution: Information not provided - ES

ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma - ES Hospital Universitario 12 de Octubre Servicio de Oncología Médica

EASE study: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel-S10 in Patients with Inherited Epidermolysis Bullosa - ES Hospital Universitario La Paz Servicio de Dermatología infantil

ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma - ES Hospital Universitario La Paz Servicio de Oncología Médica

A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma GOSH NHS Foundatin Trust Great Ormond Street Hospital

RBHIPF004 - A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease National Heart and Lung Institute, Imperial College, Royal Brompton Campus Interstitial Lung Disease Unit

Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients Institution: Information not provided - UK

EASE study: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel S10 in Patients with Inherited Epidermolysis Bullosa -GB Institution: Information not provided - UK

European Paediatric Soft Tissue Sarcoma Study Group protocol for Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas 2005 (phase III) - UK Royal Manchester Children's Hospital Department of Oncology

A multicenter, multinational, randomized, controlled, open label study, performed in children with thermal burns, to evaluate the efficacy and safety of NexoBrid as compared to standard of care (SOC) treatment (Phase III) - BE Ghent University Hospital - UZ Gent Department of Plastic Surgery

SENSCISTM-ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - BE Ghent University Hospital - UZ Gent Department of Rheumatology

SENSCIS (TM) Extension: Eine offene Verlängerungsstudie zur Beurteilung der Langzeitsicherheit von Nintedanib bei Patienten mit Systemischer Sklerose assoziierter Interstitieller Lungenerkrankung (SSc-ILD). Medizinische Hochschule Hannover Klinik für Pneumologie

AKST4290-221: Doppelblinde, randomisierte, Placebo-kontrollierte Studie mit AKST4290 zur adjuvanten Behandlung von leichtem bis mittelschwerem bullösem Pemphigoid Universitätsklinikum Carl Gustav Carus an der TU Dresden Klinik und Poliklinik für Dermatologie

Immunodeficiency in cartilage-hair hypoplasia: sub-project on safety of vaccination against chickenpox -FI HUS - Helsinki University Hospital New Children's Hospital

A randomized, double-blind, double-dummy active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris -FR Institution: Information not provided - FR

A multicenter, multinational, randomized, controlled, open label study, performed in children with thermal burns, to evaluate the efficacy and safety of NexoBrid as compared to standard of care (SOC) treatment (Phase III) - FR Institution: Information not provided - FR

MSC: Treatment of Refractory Severe Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells - (Phase I-II) - FR CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis Unité de Médecine interne, Maladies Auto-immunes et Pathologie Vasculaire

RITUX-MMP : Randomized Double Blind Double Dummy Control Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid (Phase III) CHU de Rouen Clinique dermatologique

PEMPA : Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid (Phase III) CHU de Bordeaux - Hôpital Saint André Service de Dermatologie adulte et pédiatrique

EBTox : Evaluation of the Efficacy of Injections of Botulinic Toxin in Plantar Lesions of Patients Suffering From Localized Epidermolysis Bullosa Simplex : Double Blind Randomized Controlled Study (Phase II-III) CHU de Toulouse - Hôpital Larrey Centre de référence des maladies rares de la peau

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - IE St. Vincent's University Hospital CF Clinic

An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa (phase III) - IT IRCCS Ca' Granda - Ospedale Maggiore Policlinico - Clinica Pediatrica De Marchi U.O.S. di Infettivologia Pediatrica

ASTIS: High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis (Phase III) - IT AOU Careggi Dipartimento di Biomedicina

Randomized Controlled Trial for Testing the Efficacy of Well-Being Therapy in Patients With Systemic Sclerosis Università degli studi di Firenze Dipartimento di Scienze della Salute

The MANUS Trial: Mesenchymal Stromal Cells for Angiogenesis and Neovascularisation in Digital Ulcers of Systemic Sclerosis (Phase II) UMC Utrecht - Universitair Medisch Centrum Utrecht Afdeling Nefrologie

A Multicenter, Multinational, Randomized, Controlled, Open Label Study, Performed in Children With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid as Compared to Standard of Care (SOC) Treatment (Phase 3) - AT Institution: Information not provided - AT

An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD) (Phase 3) - AT Institution: Information not provided - AT

An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) (Phase 2) - AT Institution: Information not provided - AT

Effectiveness and safety of Dimethylfumarate in patients with Palmoplantar Pustulosis - a 24-week, open label, phase II trial Allgemeines Krankenhaus der Stadt Wien Universitätsklinik für Dermatologie

Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study Allgemeines Krankenhaus der Stadt Wien Universitätsklinik für klinische Pharmakologie

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - CH Institution: Information not provided - CH

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES Hospital Universitari Vall d'Hebron Servicio de Medicina Interna

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES Hospital de la Santa Creu i Sant Pau Servicio de Medicina Interna

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES Hospital Universitario Doctor Peset

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES Hospital Universitario y Politécnico La Fe

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES Hospital Álvaro Cunqueiro

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES Hospital General Universitario Gregorio Marañón

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES Hospital Universitario 12 de Octubre

A multicenter, multinational, randomized, controlled, open label study, performed in children with thermal burns, to evaluate the efficacy and safety of NexoBrid as compared to standard of care (SOC) treatment (Phase III) - ES Hospital Universitario La Paz Servicio de Cirugía pediátrica

An Open Label Extension, Multi-Center, Study to Evaluate the Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa (Terminated) - US Children's Hospital of Chicago

A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis University of Washington

A short-term open-label single site pilot study evaluating the use of asasantin retard therapy in the management of Raynaud's phenomenon Royal National Hospital for Rheumatic Disease Department of Rheumatology

Treatment of Pustular Psoriasis with the IL-1 receptor antagonist anakinra: a randomised, placebo controlled trial and associated mechanistic studies King's College London King's College London Headquarters

Treatment of Pustular Psoriasis with the IL-1 receptor antagonist anakinra: a randomised, placebo controlled trial and associated mechanistic studies Kings College School of Medicine Guy's and St Thomas NHS Foundation Trust

A Phase II/III, Multicenter, Randomized, Double Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis - UK Institution: Information not provided - UK

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)GB Institution: Information not provided - UK

EXIST-LT: Long-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301- BE
Universitair Ziekenhuis Brussel

Pediatric neurology / Neurologie Kinderen

NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - BE
UZ Leuven - Campus Gasthuisberg

Department of Human Genetics

EASE study: Double Blind, Randomised, Vehicle Controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa - BE
UZ Leuven - Campus Gasthuisberg

Reference centre for inherited Epidermolysis Bullosa

Effectiveness and safety of mTOR-inhibitor in patients with tuberous sclerosis complex-KD
Universitätsklinikum Heidelberg

PazoQol: Lebensqualität bei Patienten mit nicht-adipozytärem Weichgewebssarkom unter palliativer Chemotherapie oder Pazopanib -eine randomisierte, kontrollierte Studie
Helios Klinikum Emil von Behring

Klinik für Onkologie

OlaReDo: Wirksamkeit von Olaratumab und Wiederauftreten mit Doxorubicin bei Anthrazyklin vorbehandelten, fortgeschrittenen Weichteilsarkompatienten. Eine explorative Phase-II-Studie
Krankenhaus Nordwest GmbH

Institut für Klinisch-Onkologische Forschung

EXIST-2: A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) - ES (Phase III)
Institution: Information not provided - FR

Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 - FR
CHU de Nantes

CHU Nantes

EASE study: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel S10 in Patients with Inherited Epidermolysis Bullosa - IE
Children's Health Ireland @ Crumlin

Dermatology Department

European Paediatric Soft Tissue Sarcoma Study Group protocol for Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas 2005 (phase III) - IE
Children's Health Ireland @ Crumlin

National Oncology/ Bone Marrow Transplant Centre and Haematology Department

EASE study: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel S10 in Patients with Inherited Epidermolysis Bullosa - IE
St James's Hospital

Dermatology Department

A Phase 1/2 Study of ARQ 092 in Patients with Overgrowth Diseases and/or Vascular Anomalies with Genetic Alterations of the PI3K/AKT Pathway
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO

Ambulatorio Polispecialistico per le Malattie Rare

High dose intravenous N-Acetylcysteine vs Iloprost for Early, rapidly progressive diffuse systemic Sclerosis
Università Politecnica delle Marche - Polo Didattico

Istituto di Clinica Medica

Low-dose oral Imatinib in the treatment of Scleroderma pulmonary involvement: a phase II pilot sutdy
Università Politecnica delle Marche - Polo Didattico

Istituto di Clinica Medica

RATE trial: Randomised open label cross-over study into the efficacy of rapamycin in children with Tuberous Sclerosis Complex with intractable epilepsy (phase II/III trial)
Erasmus MC - Erasmus Medisch Centrum

Afdeling Kinderneurologie

RAPIT trial: Efficacy of RAD001/everolimus in Autism and NeuroPsychological deficits in children with TSC (phase II/III trial)
Erasmus MC - Erasmus Medisch Centrum

Afdeling Kinderneurologie

NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL
Erasmus MC - Erasmus Medisch Centrum

Afdeling Kinderneurologie

NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - NL
Erasmus MC - Erasmus Medisch Centrum

Afdeling Neurowetenschappen

NF1-EXCEL: The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial - BE
Erasmus MC - Erasmus Medisch Centrum

EASE: Double Blind, Randomised, Vehicle Controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa - AT
Universitätsklinikum der Paracelsus Medizinischen Privatuniversität

EB-Haus Austria

REGO-SARC: Activity and Safety of Regorafenib in Patients With Metastatic Soft Tissue Sarcoma Previously Treated With Anthracycline-based Chemotherapy: a Multinational, Randomized, Phase II, Placebo-controlled Trial - AT
Allgemeines Krankenhaus der Stadt Wien

Klinische Abteilung für Onkologie

EASE study: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel S10 in Patients with Inherited Epidermolysis Bullosa - CH
University Hospital Inselspital

Poliklinik für Dermatologie

ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized,Double-Blinded) Study Evaluating Gemcitabine andDocetaxel With or Without Olaratumab in the Treatment ofAdvanced Soft Tissue Sarcoma -GB
Institution: Information not provided - CH

PazoQol: Quality of life in patients with non-adipocyte soft tissue sarcoma underpalliative chemotherapy or pazopanib - a randomized, controlled trial - CH
Institution: Information not provided - CH

GEIS-51: Phase II multicenter trial of palbociclib in second line of advanced sarcomas with CDK4 overexpression - ES
Hospital Universitario Virgen del Rocío

MUsculoSkeletal Tumor Board of Excellence Sevilla (MUSTBE SEVILLA)

EASE study: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel-S10 in Patients with Inherited Epidermolysis Bullosa - ES
Hospital Viamed Santa Ángela de la Cruz

Servicio de Dermatología

GEIS-51: Phase II multicenter trial of palbociclib in second line of advanced sarcomas with CDK4 overexpression - ES
ICO Badalona - Hospital Germans Trias i Pujol

Servicio de Oncología Médica

EASE study: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel-S10 in Patients with Inherited Epidermolysis Bullosa - ES
Hospital Universitari Vall d'Hebron

Servicio de Cirugía Plástica y Quemados

ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma - ES
Hospital Universitari Vall d'Hebron

Servicio de Oncología Médica

EASE study: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel-S10 in Patients with Inherited Epidermolysis Bullosa - ES
Hospital Sant Joan de Déu Barcelona

Servicio de Dermatología

A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects with Gorlin Syndrome (Basal Cell Nevus Syndrome) - ES
Institution: Information not provided - ES

ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma - ES
Hospital Universitario 12 de Octubre

Servicio de Oncología Médica

EASE study: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel-S10 in Patients with Inherited Epidermolysis Bullosa - ES
Hospital Universitario La Paz

Servicio de Dermatología infantil

ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma - ES
Hospital Universitario La Paz

Servicio de Oncología Médica

A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma
GOSH NHS Foundatin Trust

Great Ormond Street Hospital

RBHIPF004 - A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease
National Heart and Lung Institute, Imperial College, Royal Brompton Campus

Interstitial Lung Disease Unit

Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
Institution: Information not provided - UK

EASE study: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel S10 in Patients with Inherited Epidermolysis Bullosa -GB
Institution: Information not provided - UK

European Paediatric Soft Tissue Sarcoma Study Group protocol for Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas 2005 (phase III) - UK
Royal Manchester Children's Hospital

Department of Oncology

A multicenter, multinational, randomized, controlled, open label study, performed in children with thermal burns, to evaluate the efficacy and safety of NexoBrid as compared to standard of care (SOC) treatment (Phase III) - BE
Ghent University Hospital - UZ Gent

Department of Plastic Surgery

SENSCISTM-ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - BE
Ghent University Hospital - UZ Gent

Department of Rheumatology

SENSCIS (TM) Extension: Eine offene Verlängerungsstudie zur Beurteilung der Langzeitsicherheit von Nintedanib bei Patienten mit Systemischer Sklerose assoziierter Interstitieller Lungenerkrankung (SSc-ILD).
Medizinische Hochschule Hannover

Klinik für Pneumologie

AKST4290-221: Doppelblinde, randomisierte, Placebo-kontrollierte Studie mit AKST4290 zur adjuvanten Behandlung von leichtem bis mittelschwerem bullösem Pemphigoid
Universitätsklinikum Carl Gustav Carus an der TU Dresden

Klinik und Poliklinik für Dermatologie

Immunodeficiency in cartilage-hair hypoplasia: sub-project on safety of vaccination against chickenpox -FI
HUS - Helsinki University Hospital

New Children's Hospital

A randomized, double-blind, double-dummy active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris -FR
Institution: Information not provided - FR

A multicenter, multinational, randomized, controlled, open label study, performed in children with thermal burns, to evaluate the efficacy and safety of NexoBrid as compared to standard of care (SOC) treatment (Phase III) - FR
Institution: Information not provided - FR

MSC: Treatment of Refractory Severe Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells - (Phase I-II) - FR
CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis

Unité de Médecine interne, Maladies Auto-immunes et Pathologie Vasculaire

RITUX-MMP : Randomized Double Blind Double Dummy Control Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid (Phase III)
CHU de Rouen

Clinique dermatologique

PEMPA : Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid (Phase III)
CHU de Bordeaux - Hôpital Saint André

Service de Dermatologie adulte et pédiatrique

EBTox : Evaluation of the Efficacy of Injections of Botulinic Toxin in Plantar Lesions of Patients Suffering From Localized Epidermolysis Bullosa Simplex : Double Blind Randomized Controlled Study (Phase II-III)
CHU de Toulouse - Hôpital Larrey

Centre de référence des maladies rares de la peau

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - IE
St. Vincent's University Hospital

CF Clinic

An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa (phase III) - IT
IRCCS Ca' Granda - Ospedale Maggiore Policlinico - Clinica Pediatrica De Marchi

U.O.S. di Infettivologia Pediatrica

ASTIS: High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis (Phase III) - IT
AOU Careggi

Dipartimento di Biomedicina

Randomized Controlled Trial for Testing the Efficacy of Well-Being Therapy in Patients With Systemic Sclerosis
Università degli studi di Firenze

Dipartimento di Scienze della Salute

The MANUS Trial: Mesenchymal Stromal Cells for Angiogenesis and Neovascularisation in Digital Ulcers of Systemic Sclerosis (Phase II)
UMC Utrecht - Universitair Medisch Centrum Utrecht

Afdeling Nefrologie

A Multicenter, Multinational, Randomized, Controlled, Open Label Study, Performed in Children With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid as Compared to Standard of Care (SOC) Treatment (Phase 3) - AT
Institution: Information not provided - AT

An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD) (Phase 3) - AT
Institution: Information not provided - AT

An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS) (Phase 2) - AT
Institution: Information not provided - AT

Effectiveness and safety of Dimethylfumarate in patients with Palmoplantar Pustulosis - a 24-week, open label, phase II trial
Allgemeines Krankenhaus der Stadt Wien

Universitätsklinik für Dermatologie

Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study
Allgemeines Krankenhaus der Stadt Wien

Universitätsklinik für klinische Pharmakologie

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - CH
Institution: Information not provided - CH

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital Universitari Vall d'Hebron

Servicio de Medicina Interna

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital de la Santa Creu i Sant Pau

Servicio de Medicina Interna

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital Universitario Doctor Peset

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital Universitario y Politécnico La Fe

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital Álvaro Cunqueiro

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital General Universitario Gregorio Marañón

An open-label extension trial to assess the long term safety of nintedanib in patients with 'Systemic Sclerosis associated Interstitial Lung Disease' (SSc-ILD) (Phase III) - ES
Hospital Universitario 12 de Octubre

A multicenter, multinational, randomized, controlled, open label study, performed in children with thermal burns, to evaluate the efficacy and safety of NexoBrid as compared to standard of care (SOC) treatment (Phase III) - ES
Hospital Universitario La Paz

Servicio de Cirugía pediátrica

An Open Label Extension, Multi-Center, Study to Evaluate the Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa (Terminated) - US
Children's Hospital of Chicago

A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis
University of Washington

A short-term open-label single site pilot study evaluating the use of asasantin retard therapy in the management of Raynaud's phenomenon
Royal National Hospital for Rheumatic Disease

Department of Rheumatology

Treatment of Pustular Psoriasis with the IL-1 receptor antagonist anakinra: a randomised, placebo controlled trial and associated mechanistic studies
King's College London

King's College London Headquarters

Treatment of Pustular Psoriasis with the IL-1 receptor antagonist anakinra: a randomised, placebo controlled trial and associated mechanistic studies
Kings College School of Medicine

Guy's and St Thomas NHS Foundation Trust

A Phase II/III, Multicenter, Randomized, Double Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis - UK
Institution: Information not provided - UK

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)GB
Institution: Information not provided - UK

Cold Challenge With C21 in RP
Salford Royal NHS Foundation Trust

University of Manchester Rheumatic Diseases Centre

NOVESA study: A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic sclerosis - BE
Ghent University Hospital - UZ Gent

Department of Rheumatology

RESOLVE-1: Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Lenabasum bei diffuser kutaner systemischer Sklerose
Universitätsklinikum Freiburg

RESOLVE-1: Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Lenabasum bei diffuser kutaner systemischer Sklerose
Universitätsklinikum Heidelberg